Abstract
An increasing amount of ligand binding data on G protein-coupled receptors (GPCRs) is not compatible with the prediction of the simple mass action law. This may be related to the propensity of most GPCRs, if not all, to oligomerize. Indeed, one of the consequences of receptor oligomerization could be a possible cross-talk between the protomers, which in turn could lead to negative or positive cooperative ligand binding. We prove here that this can be demonstrated experimentally. Saturation, dissociation, and competition binding experiments were performed on vasopressin and oxytocin receptors expressed in Chinese hamster ovary or COS-7 cells. Linear, concave, and convex Scatchard plots were then obtained, depending on the ligand used. Moreover, some competition curves exhibited an increase of the radiotracer binding for low concentrations of competitors, suggesting a cooperative binding process. These data demonstrate that various vasopressin analogs display either positive or negative cooperative binding. Because positive cooperative binding cannot be explained without considering receptor as multivalent, these binding data support the concept of GPCR dimerization process. The results, which are in good accordance with the predictions of previous mathematical models, suggest that binding experiments can be used to probe the existence of receptor dimers.
Footnotes
-
This work was supported by the research grants from the Centre National de la Recherche Scientifique, from the Institut National de la Santé etdela Recherche Médicale, by grants from ACI Molécules Cibles et Thérapeutiques no. 240 and 355, by National Institutes of Health grant GM25280, and by the European Strep Program LSHB-CT-2003-503337.
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; CHO, Chinese hamster ovary; AVP, arginine vasopressin; OT, oxytocin; HO-LVA, 4-OH-phenylacetyl-d-Tyr(Me)2,Phe3,Gln4,Asn5,Arg6,Pro7,Arg8-NH29; OTA, d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr-NH29]vasotocin; GTPγS, guanosine 5′-O-(3-thio)triphosphate; HA, hemagglutinin; 6His, hexahistidine; FRET, fluorescence resonance energy transfer; U69593, (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide.
- Received April 13, 2006.
- Accepted August 22, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|